President-elect Donald Trump’s nomination of Robert F. Kennedy Jr. as U.S. Secretary of Health and Human Services (HHS) grabbed headlines globally, but the political jostling to come will determine ...

Med-tech companies raised $7.35 billion in the third quarter of 2024, slightly down from $7.49 billion in the second quarter but up from $6.45 billion in Q1. Through the first three quarters of the ...

Artificial intelligence-powered rare disease diagnostics firm 3billion Inc. debuted on the tech-heavy Kosdaq board of the Korea Exchange Nov. 14 with its IPO raising about ₩14.4 billion (US$10.25 ...

Makers of devices and diagnostics face a new set of policy questions following the 2024 U.S. general elections, but many of the impending changes at the executive branch seem directed more toward ...

Celltrion Inc. said it would acquire Iqone Healthcare Switzerland SA in the fourth quarter of 2024 for about ₩30 billion (US$21.34 million) to expand its European business. “This move represents a ...

Merck & Co. Inc. has in-licensed Lanova Medicines Ltd.’s PD-1/VEGF bispecific antibody LM-299 in a deal worth up to $2.7 billion in a move to bolster its Keytruda (pembrolizumab) fortress. Under terms ...

Vitalli Bio Inc. terminated a potential $477 million licensing deal for autoimmune disease drug, DWP-213388, signed a year ago with Daewoong Pharmaceutical Co. Ltd., although Vitalli still retains ...

While women make up half the world’s population and own two out of every five businesses, there are substantial knowledge gaps about conditions affecting their health – mostly due to decades of ...

Copyright ©2024. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing Manage cookie preferences ...

EA Pharma Co. Ltd. has described 2-amino-3-carboxymuconate-6-semialdehyde decarboxylase (ACMSD) inhibitors reported to be useful for the treatment of age-related issues, as well as inflammatory, ...

The EMA has changed its mind about an earlier decision that the risks of Leqembi (lecanemab) outweigh the benefits and is now recommending the Alzheimer’s disease drug is approved for a subgroup of ...

Poseida Therapeutics Inc. has updated progress made in its early-stage pipeline of differentiated T stem cell memory cell-rich allogeneic CAR T therapies in oncology and autoimmune diseases.